Teritusumab/Telicot use contraindications and unwell populations

Teritusumab (Teclistamab-cqyv) is an immunotherapy drug mainly used to treat multiple myeloma (MM) and other blood system diseases. Although it has shown good clinical efficacy, not all patients are suitable for this drug. The contraindications and unsuitable groups for the use of teritusumab mainly include the following categories:

1. Patients with known allergy to teritusumab components: If patients are known to be allergic to teritusumab or any of its components, they should avoid using this drug. This may cause allergic reactions including rash, shortness of breath, throat swelling, etc.

2. Patients with severely impaired immune function: Since this drug treats blood system diseases by activating the immune system, patients with extremely low immune system function may face the problem of excessive immune activation when used, which may not only lead to poor treatment effects, but may also cause serious immune-related side effects, such as cytokine release syndrome.

3. Pregnant and lactating women: Although there is currently no sufficient evidence to prove the direct impact of this drug on the fetus, considering the potential risks, pregnant women are generally not recommended to use such immunotherapy drugs. For nursing mothers, although it is unclear whether the drug will be passed to the baby through breast milk, for the safety of the baby, it is best to avoid breastfeeding during use.

4. Patients with severe cardiovascular disease: Teritusumab may cause certain cardiovascular problems. Especially for patients with a history of severe heart disease, its use may increase heart-related risks.

Overall, the use of teritolumab should be comprehensively considered based on the individual's health status, disease characteristics, and possible drug interactions. Before treatment, patients should fully communicate with their doctors to ensure the adaptability of the drug to their own conditions to reduce side effects and risks.

Keyword tags: teritusumab,Teclistamab, contraindications, immune function, pregnant women, liver function, cardiovascular disease

References:https://www.mayoclinic.org/drugs-supplements/teclistamab-cqyv-subcutaneous-route/description/drg-20545969